Bulk up or slim down? Maybe both: Pfizer said to weigh a $100B deal for AstraZeneca
21.04.2014 / Fierce Pharma
We thought Pfizer was on a diet. After all, CEO Ian Read has garnered investor acclaim for his unit sales and spinoffs, and more of that action is expected. But the U.S.-based drug behemoth reportedly made a $100 billion-plus merger pitch to its struggling rival AstraZeneca. That would be quite a deal to digest.